Brief: Study Demonstrates Macrolide-Resistance In S. Pneumoniae In The United States Exceeds 25 Percent Threshold Set In Current Community-Acquired Bacterial Pneumonia (Cabp) Treatment Guidelines
23/02/2021 12:21
Feb 23 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* STUDY DEMONSTRATES MACROLIDE-RESISTANCE IN S. PNEUMONIAE
IN THE
UNITED STATES EXCEEDS 25 PERCENT THRESHOLD SET IN CURRENT
COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) TREATMENT
GUIDELINES
Source text for Eikon: ID:nGNX3qqK3v
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update